BANK VONTOBEL/PUT/ROCHE GS/260/0.1/20.12.24 Share Price

Warrant

DE000VM2JVK0

Delayed Deutsche Boerse AG 13:02:09 03/07/2024 BST
2.01 EUR +4.15% Intraday chart for BANK VONTOBEL/PUT/ROCHE GS/260/0.1/20.12.24
Current month+0.52%
1 month-42.90%
Date Price Change
03/07/24 2.01 +4.15%
02/07/24 1.93 +4.89%
01/07/24 1.84 -4.17%
28/06/24 1.92 +2.13%
27/06/24 1.88 -3.09%

Delayed Quote Deutsche Boerse AG

Last update July 03, 2024 at 01:02 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM2JVK
ISINDE000VM2JVK0
Date issued 15/09/2023
Strike 260 CHF
Maturity 20/12/2024 (170 Days)
Parity 10 : 1
Emission price 2.16
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.88
Lowest since issue 1.62
Spread 0.01
Spread %0.49%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
248.5 CHF
Average target price
278.3 CHF
Spread / Average Target
+11.98%
Consensus